Natera (NTRA) Issues Earnings Results

Natera (NASDAQ:NTRA) posted its earnings results on Thursday. The medical research company reported ($0.49) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.03), Briefing.com reports. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The firm had revenue of $65.30 million during the quarter, compared to the consensus estimate of $66.42 million. During the same quarter last year, the firm posted ($0.51) EPS. The business’s revenue was up 16.8% on a year-over-year basis. Natera updated its FY 2018 guidance to EPS.

Shares of NASDAQ:NTRA traded down $3.83 during trading on Friday, reaching $16.80. The stock had a trading volume of 4,391,474 shares, compared to its average volume of 457,138. Natera has a 52 week low of $8.60 and a 52 week high of $29.62. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.00 and a beta of 2.11.

In related news, COO Steven Leonard Chapman sold 45,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $25.16, for a total value of $1,132,200.00. Following the completion of the transaction, the chief operating officer now owns 16,628 shares in the company, valued at approximately $418,360.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Michael Burkes Brophy sold 108,108 shares of the business’s stock in a transaction that occurred on Friday, September 14th. The stock was sold at an average price of $24.31, for a total transaction of $2,628,105.48. Following the completion of the transaction, the chief financial officer now owns 22,000 shares of the company’s stock, valued at approximately $534,820. The disclosure for this sale can be found here. Insiders sold 2,014,988 shares of company stock valued at $48,674,710 in the last quarter. 13.18% of the stock is currently owned by corporate insiders.

Hedge funds have recently bought and sold shares of the stock. A.R.T. Advisors LLC bought a new position in Natera in the 1st quarter worth approximately $164,000. State Board of Administration of Florida Retirement System bought a new position in Natera in the 2nd quarter worth approximately $200,000. Meeder Asset Management Inc. raised its position in Natera by 920.5% in the 3rd quarter. Meeder Asset Management Inc. now owns 8,399 shares of the medical research company’s stock worth $200,000 after purchasing an additional 7,576 shares during the last quarter. Paradigm Capital Management Inc. NY bought a new position in Natera in the 2nd quarter worth approximately $207,000. Finally, Cubist Systematic Strategies LLC bought a new position in Natera in the 2nd quarter worth approximately $252,000. Hedge funds and other institutional investors own 67.46% of the company’s stock.

NTRA has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 target price for the company in a research note on Tuesday, July 17th. BidaskClub upgraded shares of Natera from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, July 17th. Piper Jaffray Companies lifted their target price on shares of Natera to $27.00 and gave the company an “overweight” rating in a research note on Thursday, August 9th. Craig Hallum lifted their target price on shares of Natera from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. Finally, TheStreet upgraded shares of Natera from a “d” rating to a “c-” rating in a research note on Thursday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $28.25.

WARNING: “Natera (NTRA) Issues Earnings Results” was first published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this article on another domain, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The legal version of this article can be read at https://www.thelincolnianonline.com/2018/11/10/natera-ntra-issues-earnings-results.html.

About Natera

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: Google Finance

Earnings History for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply